Europe is equipping itself with a further Covid vaccine, thus increasing the weapons already available against the SarsCoV2 virus.
Thanks to the new contract that the EU Commission has signed with the French pharmaceutical company Wave, it will be possible to purchase 27 million doses of the VLA2001 vaccine for 2022. The contract includes the possibility of adapting the Valneva vaccine to new variants and allows Member States to order up to 33 million additional doses in 2023.
This is the only inactivated virus anti-Covid vaccine in Europe, and it is made up of inactivated whole viral particles of SarsCoV2. The general objective therefore remains to further incentivize vaccination campaigns in member countries, even in the face of the surge in cases in various nations.
For this reason, the vaccination of younger children aged 5 to 11 years will also be particularly important once the European Medicines Agency EMA has completed the evaluation of the vaccine already started. Pfizer for children, with a ruling expected in December.
Yesterday theEma announced that it has also begun evaluating the application submitted by the company Modern to get the green light to use its Spikevax Covid vaccine for children aged 6 to 11. And that's exactly what spikevax It is at the center of attention in Germany, where the Stiko vaccine commission has advised people under 30 to be vaccinated only with the Pfizer-Biontech immunizer.
According to the experts of the independent commission, which generally takes a more cautious line than the German government, in under-30s, both male and female, more cases of pericarditis and inflammation of the heart muscles have been observed after the administration of Moderna. As for Merck's antiviral pill (molnupiravir) - on whose emergency use the Italian Medicines Agency is awaiting a ruling - the hypothesis advanced in recent days that it could cause the emergence of new variants of the virus does not seem to be a cause for concern.
An article in Science in fact pours oil on troubled waters after Forbes reported William A. Haseltine, a scientist and entrepreneur, has expressed concern about the possibility that the antiviral's mechanism of action could select new mutations of the SarsCoV2 virus. The danger, according to Science, is currently only theoretical
Article published on November 11, 2021 - 11:44
Video Chronicles
